-
Longitudinal changes in maternal corin and mid-regional proatrial natriuretic peptide in women at risk of pre-eclampsia.
Khalil A, Maiz N, Garcia-Mandujano R, Elkhouli M, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:190-8. pdf -
Maternal serum placental growth factor isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks' gestation in late-onset pre-eclampsia and small for gestational age neonates.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014;35:249-57. pdf -
Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation.
Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014;35:240-8. pdf -
Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation.
Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014;36:9-17. pdf -
Maternal Serum Placental Growth Factor (PlGF) Isoforms 1 and 2 at 11-13 Weeks' Gestation in Normal and Pathological Pregnancies.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014;36:106-16.. pdf -
First-trimester maternal factors and biomarker screening for preeclampsia.
Poon LC, Nicolaides KH.
Prenat Diagn 2014;34:618-27. pdf -
Combined screening for preeclampsia and small for gestational age at 11-13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013;33:16-27. -
Maternal serum retinol-binding protein-4 at 11-13weeks' gestation in normal and pathological pregnancies.
Nanda S, Nikoletakis G, Markova D, Poon LC, Nicolaides KH.
Metabolism 2013;62:814-9. -
Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013;33:164-72. -
Asymmetric dimethylarginine, arginine and homoarginine at 11-13 weeks' gestation and preeclampsia: a case-control study.
Khalil AA, Tsikas D, Akolekar R, Jordan J, Nicolaides KH.
J Hum Hypertens 2013;27:38-43. -
Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013;33:8-15. -
Maternal serum human placental growth hormone (hPGH) at 11 to 13 weeks of gestation in preeclampsia.
Sifakis S, Akolekar R, Mantas N, Kappou D, Nicolaides KH.
Hypertens Pregnancy 2011;30:74-82. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 Weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Cruz JJ, Penco JM, Zhou Y, Nicolaides KH.
Hypertens Pregnancy 2011;30:194-202. -
Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks.
Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:662-70. -
First trimester urinary placental growth factor and development of pre-eclampsia.
Savvidou M, Akolekar R, Zaragoza E, Poon L, Nicolaides K.
BJOG 2009;116:643-7. -
First-trimester prediction of hypertensive disorders in pregnancy.
Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH.
Hypertension 2009;53:812-8. -
Angiotensin II type 1 and 2 receptors gene polymorphisms in pre-eclampsia and normal pregnancy in three different populations.
Akbar SA, Khawaja NP, Brown PR, Tayyeb R, Bamfo J, Nicolaides KH.
Acta Obstet Gynecol Scand 2009;88:606-11.